Skip to main content
All lobbying clients

CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP)

Lobbying client · District of Columbia · filed 2025 to 2026

Coalition to promote lowering prescription drug prices.

$330,000 Reported spend
8 Filings counted
2 Outside firms hired
29 Bills named

Spend is reported income plus in-house expenses across 8 filings. The LDA keeps a separate client record for every registrant that files for a client, so this page adds up 2 records, one per registrant listed below. Records are combined when the client name matches once case, punctuation and endings such as Inc. or LLC are set aside; for a city, county or port the state has to match as well.

 Who filed for this client 2

Spend per registrant: fees an outside firm reported, or the costs the client reported for lobbying in-house. The rows add up to the total above.

 Bills named in these filings 29
  • H.R. 1843
    To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
    6 filings
  • S. 1032
    Major Richard Star Act
    6 filings
  • S. 1040
    Drug Competition Enhancement Act
    6 filings
  • S. 1041
    Affordable Prescriptions for Patients Act
    6 filings
  • S. 1095
    Stop STALLING Act
    6 filings
  • S. 1096
    Preserve Access to Affordable Generics and Biosimilars Act
    6 filings
  • S. 1097
    Interagency Patent Coordination and Improvement Act of 2025
    6 filings
  • S. 229
    DTC Act of 2025
    6 filings
  • S. 43
    Skinny Labels, Big Savings Act
    6 filings
  • H.R. 3010
    No Handouts for Drug Advertisements Act
    5 filings
  • H.R. 3152
    Patent Eligibility Restoration Act of 2025
    5 filings
  • H.R. 3160
    PREVAIL Act
    5 filings
  • S. 1533
    A bill to amend title 38, United States Code, to make permanent and codify the pilot program for use of contr…
    5 filings
  • S. 1546
    Patent Eligibility Restoration Act of 2025
    5 filings
  • S. 1785
    No Handouts for Drug Advertisements Act
    5 filings
  • S. 1954
    Biosimilar Red Tape Elimination Act
    5 filings
  • H.R. 3269
    ETHIC Act
    4 filings
  • H.R. 3789
    DTC Act of 2025
    4 filings
  • H.R. 4570
    Interagency Patent Coordination and Improvement Act of 2025
    4 filings
  • H.R. 5526
    Biosimilar Red Tape Elimination Act
    4 filings
  • S. 2276
    ETHIC Act
    4 filings
  • S. 2630
    Saving NSF’s Workforce Act
    4 filings
  • S. 2658
    Medication Affordability and Patent Integrity Act
    4 filings
  • H.R. 1262
    Mikaela Naylon Give Kids a Chance Act
    3 filings
  • H.R. 6485
    Skinny Labels, Big Savings Act
    3 filings
  • S. 1414
    Expedited Access to Biosimilars Act
    2 filings
  • S. 3014
    Ensuring Timely Access to Generics Act of 2025
    2 filings
  • S. 5573
    Skinny Labels, Big Savings Act
    1 filing
  • H.R. 1
    One Big Beautiful Bill Act
    1 filing
 Reported by year 2 years
  • 2026 $130,000 4 filings
  • 2025 $200,000 4 filings
 Issues lobbied 5

The count is how many filings named that issue area. A filing reports one lump figure covering every issue on it, so the money above cannot be split between them.

 Agencies and chambers lobbied 2
  • SENATE 7
  • HOUSE OF REPRESENTATIVES 6
 Recent filings 8 total
Q3 report
ENDGAME STRATEGIES, LLC
3rd Quarter 2026 (July 1 - Sep 30) · Senate · $30,000 income · posted Oct 20, 2026
View → Registration
ENDGAME STRATEGIES, LLC
3rd Quarter 2026 (July 1 - Sep 30) · posted Aug 5, 2026
View → Q2 termination
WHITMER & WORRALL, LLC
2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $50,000 income · posted Jul 22, 2026
View → Q1 report
WHITMER & WORRALL, LLC
1st Quarter 2026 (Jan 1 - Mar 31) · House · Senate · $50,000 income · posted Apr 21, 2026
View → Q4 report
WHITMER & WORRALL, LLC
4th Quarter 2025 (Oct 1 - Dec 31) · House · Senate · $50,000 income · posted Jan 21, 2026
View → Q3 report
WHITMER & WORRALL, LLC
3rd Quarter 2025 (July 1 - Sep 30) · House · Senate · $50,000 income · posted Oct 20, 2025
View → Q2 report
WHITMER & WORRALL, LLC
2nd Quarter 2025 (Apr 1 - June 30) · House · Senate · $50,000 income · posted Jul 21, 2025
View → Q1 report
WHITMER & WORRALL, LLC
1st Quarter 2025 (Jan 1 - Mar 31) · House · Senate · $50,000 income · posted Apr 21, 2025
View →

Keep going

Filings through , the newest posted date on this record. Source: federal Lobbying Disclosure Act filings, synced daily. Money is self-reported by the filer and often rounded. Lobbying is legal, disclosed activity.

Report a problem